Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile AKT1 E17K
Therapy Miransertib
Indication/Tumor Type ovarian carcinoma
Response Type predicted - sensitive

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
AKT1 E17K ovarian carcinoma predicted - sensitive Miransertib Case Reports/Case Series Actionable In a clinical case study, Miransertib (ARQ092) treatment resulted in complete tumor remission and improved quality of life in a patient harboring AKT1 E17K who had Proteus syndrome and developed ovarian carcinoma, and treatment was ongoing at 22 months (PMID: 31058421). 31058421
PubMed Id Reference Title Details
(31058421) First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma. Full reference...